The prognostic influence of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in stage III non-small cell lung cancer (NSCLC) treated with consolidation durvalumab. Changes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results